Skip to main content

Table 3 Per-patient and population level costs for the interventions included in the analysis

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Patient-level
Treatment strategy Added costs for a novel or group 5 intervention (€) Cost of BR treatment Hospitalization costs (€) Outpatient care (€) Monitoring costs (€) Adverse event costs of group 5 drugs (€) Total (€)
Bedaquiline plus BR 30,799 28,652 24,038 98 1970 17 85,575
Delamanid plus BR 22,829 29,626 26,362 108 2152 2 81,079
Linezolid plus BR 20,302 29,968 27,392 107 2569 121 80,460
BR only 0 30,270 28,180 119 2393 60,962
Population-level, 100 patients with MDR-TB
Bedaquiline plus BR 3,079,915 2,865,240 2,403,791 9833 197,014 1735 8,557,529
Delamanid plus BR 2,282,920 2,962,563 2,636,180 10,755 215,241 229 8,107,888
Linezolid plus BR 2,030,217 2,996,842 2,739,250 10,715 256,867 12,091 8,045,981
BR only 0 3,026,959 2,817,995 11,919 239,279 6,096,152
  1. AE adverse event, BR background regimen, TB tuberculosis, MDR-TB multidrug-resistant tuberculosis